Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong

Overview of attention for article published in Cost Effectiveness and Resource Allocation, January 2020

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (54th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 36 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 9,457 followers.

New article: Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong. https://t.co/ajf0scXs6U #melanoma #oncology

24 Jan 2020

Reply Repost Favourite

RT @herbloong: #Costeffectiveness (CE) analyses are important in healthcare decisions. Our work looking at CE of first-line #pembrolizumab…

20 Jan 2020

Reply Repost Favourite

RT @herbloong: #Costeffectiveness (CE) analyses are important in healthcare decisions. Our work looking at CE of first-line #pembrolizumab…

16 Jan 2020

Reply Repost Favourite

#Costeffectiveness (CE) analyses are important in healthcare decisions. Our work looking at CE of first-line #pembrolizumab vs. #ipilimumab & #cytotoxics in #melanoma in #hongkong setting has just been published! https://t.co/SWGpl4EaJG @CarlosWongHKU

16 Jan 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.